Eisai Co., Ltd. ESALF
Set alert
31.50 USD +1.53 +5.11%
At close · Oct 30
31.50 Day range 31.50
23.88 52-week range 35.00
- YTD
- +5.95%
- 1 year
- -1.56%
- Open
- 31.50
- Prev close
- 29.97
- Mkt cap
- 8.89B
- Vol
- 150
- Avg vol
- 298
- EPS
- 0.91
- P/E
- 34.62
More statistics
- Low
- 31.50
- High
- 31.50
- Earnings
- Nov 10, 2026
3M chart
Events in this range
- Aug 3, 2026Earnings: 0.3979; estimate 0.3408; surprise 16.75%
- Sep 29, 2026Dividend: 0.508
- Sep 30, 2026Dividend: 0.5087
Signals (12)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 4 days ago |
| SMA: Bearish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| RSI: Overbought | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate 0.3677.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | 0.3677 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 0.3408 | 0.3979 | +0.06 | +16.75% |
| May 15, 2026 | Mar 31, 2026 | 0.07825 | -0.07262 | -0.15 | -192.81% |
| Feb 9, 2026 | Dec 31, 2025 | 0.4691 | 0.3889 | -0.08 | -17.10% |
| Nov 4, 2025 | Sep 30, 2025 | 0.33 | 0.2435 | -0.09 | -26.21% |
| Aug 4, 2025 | Jun 30, 2025 | 0.2689 | 0.3563 | +0.09 | +32.50% |
News
- Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
- FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
- Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
- BioArctic Interim Report for the period January - March 2026
- Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
- Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
- These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
- Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
- Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
- BioArctic Interim Report for the period October - December 2025
Your note
Sign in to keep a note on ESALF — it syncs with the Stock Master app.